Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 62Letrozole 56Fulvestrant 55Trastuzumab 50palbociclib 42pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25abemaciclib 24Tamoxifen 24Capecitabine 24ribociclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × Selective Estrogen Receptor Modulators × Clear all
NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

University of Miami

Phase 2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡